Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Susan G who wrote (112825)	8/30/2000 2:10:25 AM
From: lizard lick	Respond to of 120523

Moving some money into KITS, looks like some impressive speculation potential here on the genomics and proteomics front for the duration. Remember old MYGN last july alerted here in the 8-10 range , well here is another one worth a go. I hope to hear another univision southamerican soccer commentator scream gooooooooaaaaaaallllllllllllll next year. Anyways worth a looksky. Meridian Announces Major Expansion of Its Biotechnology Resources CINCINNATI--(BW HealthWire)--Aug. 28, 2000-- Leveraging of Meridian's antibody capabilities Collaboration with university, biotech, and pharmaceutical partners Use of genomic and proteomic science Novel drug and vaccine discovery support, and related diagnostic assays Meridian Diagnostics, Inc., (NASDAQ: KITS - news) today announced an expansion of its capabilities in biotechnology, research reagent development, and other services that will aid in the ultimate discovery and realization of new pharmaceuticals, vaccines, and diagnostics. Meridian expects to finalize a series of licensing agreements and targeted acquisitions that will substantially broaden its opportunities to participate in the development of biopharmaceuticals and advanced diagnostics. As a leading diagnostic company with capabilities in antibody science, immunoassay, and test formatting, Meridian's core diagnostics business is well established with a strong foundation in advanced biological methodologies and processes. Meridian's new biotechnology initiative will provide the opportunity to strongly advance the Company's current broad line of innovative diagnostic tests as well as participate in the discovery and development of new drugs and vaccines. These new capabilities will provide Meridian access to the rapidly developing proteomics and biopharmaceuticals markets. John Kraeutler, President and COO, said, ``Meridian's expansion of the scope and technological capabilities of its business is strategically in line with the rapid progression of the sciences of geonomics, proteomics, drug and vaccine discovery, and advanced diagnostic methods.'' Meridian expects to announce additional details regarding its new biotechnology initiatives in the near future. Meridian Diagnostics, Inc. is a fully integrated medical diagnostic company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products. Utilizing a variety of technologies, these products provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral, urinary and respiratory infections. All Meridian products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal infections, serology, parasitology and fungal disease diagnosis. The Company markets its products to hospitals, reference laboratories, research centers and physician offices in more than 60 countries around the world. The Company's shares are traded through Nasdaq National Market, symbol KITS. Meridian Diagnostics' website address is www.meridiandiagnostics.com.